janiecbros/iStock via Getty Images Investment Overview - Recapping the Verve In Vivo Thesis It has been almost 10 months since Seeking Alpha published my last coverage of Verve Therapeutics, Inc. (NASDAQ:VERV). As a reminder, per the company's Q2 2024 quarterly report / 10Q submission, Verve is: a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic management to single-course gene editing medicines. We ...